EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class Action Filed by the Firm -- AEZS

NEW YORK, Nov. 28, 2014 (GLOBE NEWSWIRE) -- Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq: AEZS ) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.

To join the AEZS class action, go to the website at http://rosenlegal.com/cases-429.html or call Phillip Kim, Esq. or Jonathan Horne, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or jhorne@rosenlegal.com for information on the class action. The suit is pending in U.S. District Court for the District of New Jersey.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, the Company misstated information about its New Drug Application ("NDA") with the FDA. On October 18, 2012, the Company announced the Phase III clinical trial results of its drug MACRILEN™ ("MACRILEN"), stating that the results "confirm [MACRILEN's] potential as possibly the first approved oral diagnostic test for adult growth hormone deficiency." The Phase III trials were conducted pursuant to a Special Protocol Assessment that was agreed upon with the FDA. The Company then filed an NDA for MACRILEN.

On November 6, 2014, the Company announced that the FDA would not approve the Company's MACRILEN NDA, as it had received a Complete Response Letter ("CRL"). The Company stated that the FDA's concerns were:

"[T]hat the planned analysis of the Company's pivotal trial did not meet its stated primary efficacy objective as agreed to in the Special Protocol Assessment agreement letter between the Company and the FDA . The CRL further mentioned issues related to the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD. The FDA concluded that, "in light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication." To address the deficiencies identified above, the CRL states that the Company will need to demonstrate the efficacy of macimorelin as a diagnostic test for growth hormone deficiency in a new, confirmatory clinical study. " That day, the Company's stock price fell from $1.29 to $0.65, damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2015. If you wish to join the litigation go to http://rosenlegal.com/cases-429.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com .

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Laurence Rosen, Esq. Phillip Kim, Esq. Jonathan Horne, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition

Updated Category News Views 950

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition AMSURG, a prominent independent leader in ambulatory surgery center services, recently achieved a significant milestone by acquiring Pinnacle Surgery Center. This acquisition boosts AMSURG's presence in the healthcare industry, particularly in providing high-quality surgical care to communities. Overview...

Continue Reading
Montauk Renewables Announces Q2 2025 Conference Call Details

Updated Category News Views 192

Montauk Renewables Schedules Q2 2025 Conference Call Montauk Renewables, Inc. (NASDAQ: MNTK), a leading renewable energy company specializing in biogas management, will host its second quarter 2025 conference call on a Thursday morning. This session is set for August 7, 2025, at 8:30 a.m. ET, where they will present their financial results for the period ending June 30,...

Continue Reading
MaxCyte Earnings Report: What Investors Should Know

Updated Category News Views 157

MaxCyte's Earnings Announcement Overview MaxCyte (NASDAQ: MXCT) is gearing up for its quarterly earnings report. Investors are keen to see the results, especially when it comes to their earnings per share (EPS) expectations. Anticipated Earnings Performance Analysts are predicting that MaxCyte will report an EPS of $-0.10. This figure is crucial as it sets the stage for...

Continue Reading
Pluxee Expands Employee Benefits with Benefício Fácil Acquisition

Updated Category News Views 239

Pluxee Strengthens Its Presence in Brazil Through Strategic Acquisition Pluxee has made a significant move to solidify its operations in Brazil by acquiring 100% of Benefício Fácil, a leading provider of employee mobility benefits. This acquisition marks a pivotal step in reinforcing Pluxee’s position within the dynamic Brazilian market. Details of the Acquisition The...

Continue Reading
Carlyle Credit Income Fund Announces Public Offering Details

Updated Category News Views 312

Carlyle Credit Income Fund Prices New Offering of Preferred Shares In a significant development in the investment community, Carlyle Credit Income Fund (the "Fund") (NYSE: CCIF) has unveiled the details of its latest public offering. The Fund has successfully priced an underwritten public offering for 1.2 million shares of its Series D Preferred Shares, which come with a...

Continue Reading